Business Context and Reporting Period
This Form 6-K filing by Anbio Biotechnology covers the month of January 2026. The report discloses a material change in the Company's Board of Directors effective January 21, 2026.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes.
Material Changes
- Board Appointment: Michael Zhang was appointed as a director, Chair of the Audit Committee, and member of the Nominating and Compensation Committees.
- Board Departure: Kenneth Li resigned from the same positions. The filing states his departure was not due to any disagreement with the Company's operations, policies, or procedures.
- Compensation: Michael Zhang is entitled to an annual compensation of US$30,000, payable semiannually.
Outlook, Risks, and Management Commentary
The Board determined that Michael Zhang is independent under Nasdaq Listing Rules and qualifies as an "audit committee financial expert." He brings over 30 years of finance experience, including his role as a managing partner at Healthcare Alpha Management since 2014. No specific risks, contingencies, or unusual items were disclosed in this filing.
Investor Verification Checklist
- Verify the independence status of the new Audit Committee Chair, Michael Zhang.
- Confirm the transition timeline for Kenneth Li's departure and the effective date of Zhang's appointment.
- Review the full text of the Director Offer Letter (Exhibit 10.1) for additional terms.